Helsinn Healthcare SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Helsinn Healthcare SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH131650D
  • |
  • Pages: 27
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Helsinn Healthcare SA (Helsinn Healthcare), a subsidiary of Helsinn Holding SA is a cancer care company that offers oncology products and therapies. The company offers products in therapeutic areas of pain and inflammation, cancer care and gastroenterology. Its products comprise Aloxi, Gelclair, Akynzeo, Nimesulide, Klean-Prep and laxaclear. The company offers research and development programs for manufacturing of cancer supportive care, and gastroenterology products. It also offers integrated early- and late-stage licensing programs for own drug discovery and development programs. Helsinn Healthcare is headquartered in Lugano, Switzerland.

Helsinn Healthcare SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Helsinn Healthcare SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 10

Venture Financing 11

On Target Labs Raises Additional USD3.6 Million in Series B Financing 11

Partnerships 12

Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 12

Helsinn and Grunenthal Enter into Agreement for Akynzeo 13

Helsinn Healthcare Partners with University of Texas MD Anderson Cancer Center 14

Licensing Agreements 15

Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 15

Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 17

Helsinn Healthcare Enters Into Licensing Agreement With Specialised Therapeutics Australia For Anamorelin 18

Helsinn Healthcare SA-Key Competitors 19

Helsinn Healthcare SA-Key Employees 20

Helsinn Healthcare SA-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Strategy And Business Planning 22

Oct 17, 2017: Helsinn Pharmaceuticals (Beijing) Opens Office in Shanghai, China 22

Corporate Communications 23

Feb 27, 2018: Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics 23

May 18, 2017: Helsinn appoints Eric Cornut to Board of Directors 24

Government and Public Interest 25

Apr 12, 2018: Helsinn Provides Grant for ESMO's Preceptorship Programme for Supportive and Palliative Care 25

Other Significant Developments 26

Oct 19, 2017: Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt 26

Appendix 27

Methodology 27

About GlobalData 27

Contact Us 27

Disclaimer 27

List of Figures

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Key Facts 2

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Helsinn Healthcare SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Helsinn Healthcare SA, Deals By Therapy Area, 2012 to YTD 2018 8

Helsinn Healthcare SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 10

On Target Labs Raises Additional USD3.6 Million in Series B Financing 11

Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 12

Helsinn and Grunenthal Enter into Agreement for Akynzeo 13

Helsinn Healthcare Partners with University of Texas MD Anderson Cancer Center 14

Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 15

Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 17

Helsinn Healthcare Enters Into Licensing Agreement With Specialised Therapeutics Australia For Anamorelin 18

Helsinn Healthcare SA, Key Competitors 19

Helsinn Healthcare SA, Key Employees 20

Helsinn Healthcare SA, Other Locations 21

Helsinn Healthcare SA, Subsidiaries 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Helsinn Healthcare SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17815
Site License
USD 500 INR 35630
Corporate User License
USD 750 INR 53445

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com